PE20221276A1 - Formulacion de anticuerpo que contiene crizanlizumab - Google Patents
Formulacion de anticuerpo que contiene crizanlizumabInfo
- Publication number
- PE20221276A1 PE20221276A1 PE2022000689A PE2022000689A PE20221276A1 PE 20221276 A1 PE20221276 A1 PE 20221276A1 PE 2022000689 A PE2022000689 A PE 2022000689A PE 2022000689 A PE2022000689 A PE 2022000689A PE 20221276 A1 PE20221276 A1 PE 20221276A1
- Authority
- PE
- Peru
- Prior art keywords
- crizanlizumab
- formulation containing
- antibody formulation
- seq
- iso
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927720P | 2019-10-30 | 2019-10-30 | |
| US201962927716P | 2019-10-30 | 2019-10-30 | |
| US201962933692P | 2019-11-11 | 2019-11-11 | |
| US201962936269P | 2019-11-15 | 2019-11-15 | |
| PCT/US2020/057868 WO2021087050A1 (en) | 2019-10-30 | 2020-10-29 | Crizanlizumab containing antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221276A1 true PE20221276A1 (es) | 2022-09-05 |
Family
ID=73544317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000689A PE20221276A1 (es) | 2019-10-30 | 2020-10-29 | Formulacion de anticuerpo que contiene crizanlizumab |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220378912A1 (enExample) |
| EP (1) | EP4051236A1 (enExample) |
| JP (1) | JP2023501155A (enExample) |
| KR (1) | KR20220092917A (enExample) |
| CN (1) | CN114828826A (enExample) |
| AU (1) | AU2020373017B2 (enExample) |
| BR (1) | BR112022008097A2 (enExample) |
| CA (1) | CA3158921A1 (enExample) |
| CL (1) | CL2022001085A1 (enExample) |
| CO (1) | CO2022005207A2 (enExample) |
| EC (1) | ECSP22033601A (enExample) |
| IL (1) | IL292403A (enExample) |
| JO (1) | JOP20220097A1 (enExample) |
| MX (1) | MX2022005044A (enExample) |
| MY (1) | MY209141A (enExample) |
| PE (1) | PE20221276A1 (enExample) |
| PH (1) | PH12022551041A1 (enExample) |
| TW (1) | TWI893018B (enExample) |
| WO (1) | WO2021087050A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE041957T2 (hu) | 2006-12-01 | 2019-06-28 | Novartis Ag | Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére |
| JOP20190101A1 (ar) * | 2016-11-03 | 2019-05-05 | Novartis Ag | أنظمة علاج |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| CA3092931A1 (en) * | 2018-03-08 | 2019-09-12 | Novartis Ag | Use of an anti-p-selectin antibody |
-
2020
- 2020-10-29 TW TW109137726A patent/TWI893018B/zh active
- 2020-10-29 BR BR112022008097A patent/BR112022008097A2/pt unknown
- 2020-10-29 MY MYPI2022002262A patent/MY209141A/en unknown
- 2020-10-29 PH PH1/2022/551041A patent/PH12022551041A1/en unknown
- 2020-10-29 IL IL292403A patent/IL292403A/en unknown
- 2020-10-29 MX MX2022005044A patent/MX2022005044A/es unknown
- 2020-10-29 CA CA3158921A patent/CA3158921A1/en active Pending
- 2020-10-29 EP EP20811836.4A patent/EP4051236A1/en active Pending
- 2020-10-29 PE PE2022000689A patent/PE20221276A1/es unknown
- 2020-10-29 AU AU2020373017A patent/AU2020373017B2/en active Active
- 2020-10-29 US US17/771,353 patent/US20220378912A1/en active Pending
- 2020-10-29 WO PCT/US2020/057868 patent/WO2021087050A1/en not_active Ceased
- 2020-10-29 JP JP2022524914A patent/JP2023501155A/ja active Pending
- 2020-10-29 KR KR1020227017799A patent/KR20220092917A/ko active Pending
- 2020-10-29 CN CN202080075626.2A patent/CN114828826A/zh active Pending
-
2022
- 2022-04-26 CO CONC2022/0005207A patent/CO2022005207A2/es unknown
- 2022-04-27 JO JOP/2022/0097A patent/JOP20220097A1/ar unknown
- 2022-04-27 EC ECSENADI202233601A patent/ECSP22033601A/es unknown
- 2022-04-28 CL CL2022001085A patent/CL2022001085A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL292403A (en) | 2022-06-01 |
| TW202128221A (zh) | 2021-08-01 |
| WO2021087050A1 (en) | 2021-05-06 |
| CN114828826A (zh) | 2022-07-29 |
| MX2022005044A (es) | 2022-05-16 |
| ECSP22033601A (es) | 2022-05-31 |
| CA3158921A1 (en) | 2021-05-06 |
| AU2020373017B2 (en) | 2024-06-06 |
| PH12022551041A1 (en) | 2023-04-24 |
| CO2022005207A2 (es) | 2022-05-10 |
| BR112022008097A2 (pt) | 2022-08-02 |
| KR20220092917A (ko) | 2022-07-04 |
| JOP20220097A1 (ar) | 2023-01-30 |
| EP4051236A1 (en) | 2022-09-07 |
| JP2023501155A (ja) | 2023-01-18 |
| US20220378912A1 (en) | 2022-12-01 |
| CL2022001085A1 (es) | 2023-02-03 |
| AU2020373017A1 (en) | 2022-05-19 |
| MY209141A (en) | 2025-06-24 |
| TWI893018B (zh) | 2025-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210050A1 (es) | Nuevos compuestos de sulfonamida carboxamida | |
| PE20181176A1 (es) | Composiciones biofarmaceuticas | |
| ES2539812T3 (es) | Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos | |
| PE20141413A1 (es) | Formulaciones de anticuerpo y metodos | |
| CO6331346A2 (es) | Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo | |
| CO6231039A2 (es) | Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas | |
| ECSP16012693A (es) | Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y polipéptido que contiene aditivo, uso y procedimiento de los mismos | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| PE20120816A1 (es) | Composiciones que comprenden anticuerpos de dickkopf-1 | |
| CO2021014778A2 (es) | Subunidad s1 modificada de la proteína de espícula de coronavirus | |
| PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
| MX2022007881A (es) | Proteina f mutante del virus sincitial respiratorio (rsv) y usos de la misma. | |
| CO6341637A2 (es) | \\\\\\\"composiciones y metodos novedosos\\\\\\\" | |
| ES2399617T3 (es) | Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelulcar y métodos de identificación de las mismas | |
| AR086074A1 (es) | Composiciones y metodo para tratar enfermedades autoinmunes | |
| PE20211708A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r | |
| SMT201300093B (it) | Formulazioni di vwf ricombinante liofilizzate | |
| AR116876A1 (es) | Vacuna de ibv 4/91 con proteína espicular heteróloga | |
| MX2019005137A (es) | Vacuna contra parvovirus porcino. | |
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano | |
| ES2530670T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
| AR100268A1 (es) | Formulación líquida que comprende compuesto neutralizante de gm-csf | |
| CY1117335T1 (el) | Εμβολιο pcsk9 |